Adenocarcinoma of the small intestine Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Apr 2026A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Kestrel Therapeutics, Inc. — PHASE1

TrialRECRUITING

Feb 2026GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas

Thomas Jefferson University — PHASE1

TrialNOT YET RECRUITING

Jan 2026First in Human Study of QLS5316 in Solid Tumors

Qilu Pharmaceutical Co., Ltd. — PHASE1

TrialNOT YET RECRUITING

Jul 2025AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Amgen — PHASE1

TrialRECRUITING

Jul 2025Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Auricula Biosciences Inc. — PHASE1, PHASE2

TrialRECRUITING

Jun 2025Small Bowel Capsule Endoscopy in Lynch Syndrome

Assistance Publique - Hôpitaux de Paris

TrialRECRUITING

May 2025A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Arvinas Inc. — PHASE1, PHASE2

TrialRECRUITING

Apr 2025Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Cedars-Sinai Medical Center

TrialRECRUITING

Mar 2025Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Guangzhou JOYO Pharma Co., Ltd — PHASE2

TrialRECRUITING

Feb 2025A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd. — PHASE1

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Adenocarcinoma of the small intestine.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Lynparza

(olaparib)Orphan drugstandard

AstraZeneca Pharmaceuticals LP

Poly(ADP-Ribose) Polymerase Inhibitor [EPC]

12.1 Mechanism of Action Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Adenocarcinoma of the small intestine.
Search all trials →

Search clinical trials for Adenocarcinoma of the small intestine →

Recent News & Research

No recent news articles indexed yet for Adenocarcinoma of the small intestine.
Search PubMed for Adenocarcinoma of the small intestine →

Browse all Adenocarcinoma of the small intestine news →

Specialist Network

Top 5 by expertise

Lin Shen

Peking University Cancer Hospital & Institute

Score 87 trials110 pubs

Shivaani Kummar, MD

NCI - Medical Oncology Branch

📍 PORTLAND, OR

Score 55 trials

Crystal Denlinger, MD, M.D

Fox Chase Cancer Center

📍 PHILADELPHIA, PA

Score 32 trials

Robert McWilliams, MD, M.D

Mayo Clinic

📍 PEORIA, IL

Score 32 trials

Dana Cardin, MD

Vanderbilt-Ingram Cancer Center

📍 NASHVILLE, TN

Score 01 trial

View all Adenocarcinoma of the small intestine specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰